Milestone Pharmaceuticals Inc.
MIST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.07 | -0.01 | -0.07 |
| FCF Yield | -5.05% | -9.77% | -26.31% | -4.68% |
| EV / EBITDA | -17.20 | -11.90 | -3.19 | -14.31 |
| Quality | ||||
| ROIC | 0.00% | -32.00% | -41.49% | -18.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.82 | 0.97 | 0.67 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.58% | 9.86% | -103.23% | 2.24% |
| Safety | ||||
| Net Debt / EBITDA | -0.89 | -1.16 | -0.53 | -2.39 |
| Interest Coverage | 12.23 | -13.18 | -22.05 | -13.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -9,411.43 | -7,946.67 | -1,227.50 |